A Phase Ib Study of Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Latest Information Update: 10 Mar 2023
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary)
- Indications Multiple myeloma; Renal impairment
- Focus Adverse reactions
- 08 Mar 2023 Planned End Date changed from 31 Oct 2030 to 31 Mar 2027.
- 08 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2022 Status changed from not yet recruiting to recruiting.